Par Recalls More Treprostinil Due to Silicone in the Product
An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.
Par Pharmaceutical, a part of Endo International, is expanding its recall to include seven additional lots of Treprostinil Injection 20mg/20mL. The product is being recalled because of the possibility of silicone particulates in the product, the company said in a news release.
Treprostinil Injection is a prostacyclin vasodilator used to treat patients with pulmonary arterial hypertension and for patients who require transition from epoprostenol. The presence of silicone can result in local irritation or swelling at the injection site. If the silicone particulates reach the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain.
Treprostinil Injection is distributed in multidose vials as sterile solutions in water for injection with individually packaged in cartons with the NDC #42023-206-01. The lots were distributed nationwide to wholesalers and hospitals from June 16, 2022, through Aug. 7, 2023. The lots affected by this recall can be found here.
Related: Silicone Particles in Product Leads to Recall of Treprostinil
Last month, Par had recalled one lot of Treprostinil Injection for the same reason.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 31st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 31st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 31st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
